BAY 60-7550

BAY 60-7550 is a **potent and selective small molecule inhibitor** of **phosphodiesterase type 2 (PDE2A)**, developed by Bayer. It acts by preventing the hydrolysis of *cyclic adenosine monophosphate (cAMP)* and *cyclic guanosine monophosphate (cGMP)*, thereby increasing their intracellular concentrations. This mechanism leads to **enhancement of synaptic plasticity, memory performance, and anxiolytic-like effects** in animal studies. BAY 60-7550 is **brain-penetrant in mice** and has effects on cardiovascular parameters, including positive inotropy and vasodilation. Its pharmacological profile has been studied mainly in *preclinical* settings for neurological and cardiac disorders, as well as in animal models of Alzheimer's disease and heart failure[1][2][3][4][5][6][7][8][9].

Other names

BAY 60-7550BAY60-7550BAY-60-7550CAS 439083-90-6CAS439083-90-6CAS-439083-90-6